Lack of clinical activity with crizotinib in a patient with FUS rearranged rhabdomyosarcoma with ALK protein overexpression
Jeremy Lewin, Jayesh Desai, Kortnye Smith, Stephen Luen, Daniel Wong
Pathology | ELSEVIER | Published : 2019
Awarded by Melbourne Genomics Health Alliance
The NGS was available through Melbourne Genomics, funded by the State Government of Victoria (Department of Health and Human Services) and the 10 member organisations of the Melbourne Genomics Health Alliance in addition to the Australian Genomics Health Alliance (NHMRC Grant 113531). The authors state that there are no conflicts of interest to disclose.